Mesa Laboratories (NASDAQ:MLAB) Issues Quarterly Earnings Results

Mesa Laboratories (NASDAQ:MLAB) issued its earnings results on Monday. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter, reports. Mesa Laboratories had a return on equity of 22.87% and a net margin of 1.92%.The business had revenue of $60.14 million during the quarter.

Here are the key takeaways from Mesa Laboratories’ conference call:

• Revenue returned to organic growth: First-quarter revenue rose 1% to $60.1 million, while adjusted operating income increased 16.5% to $15.0 million, with adjusted margin expanding to 25.6%.
• Core franchises showed growth: Biopharmaceutical Development grew 5% organically, Calibration Solutions grew 7.6%, and trailing-12-month Sterilization and Disinfection Control revenue increased about 5%, despite quarterly delivery delays.
• SDC execution remains a key risk: Sterilization and Disinfection Control revenue declined 3.6% year over year as missed delivery dates increased past-due backlog by approximately $1 million; management characterized this as a reliability issue rather than weak demand but did not provide a recovery timetable.
• Management is prioritizing internal improvements over acquisitions: Mesa repaid $8.7 million of debt, reduced net leverage to 1.85x, and is targeting 1.5x–1.75x by fiscal year-end while reallocating resources toward higher-return businesses.
• Growth initiatives are still developing: A new BPD general manager is rebuilding the commercial organization, and Mesa accelerated development of a next-generation Gyrolab platform targeted for fiscal 2028; full-year fiscal 2027 guidance is deferred until November.

Mesa Laboratories Stock Down 0.1%

Shares of MLAB stock traded down $0.11 during trading on Wednesday, reaching $111.12. The company’s stock had a trading volume of 138,906 shares, compared to its average volume of 147,209. The stock’s 50-day moving average price is $100.34 and its 200 day moving average price is $95.50. The company has a market capitalization of $622.27 million, a price-to-earnings ratio of 132.29 and a beta of 0.92. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.72 and a quick ratio of 1.29. Mesa Laboratories has a 1-year low of $58.83 and a 1-year high of $113.99.

Mesa Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Monday, August 31st will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Monday, August 31st. Mesa Laboratories’s dividend payout ratio (DPR) is 53.33%.

Insider Buying and Selling

In other news, SVP Brian David Archbold sold 2,516 shares of Mesa Laboratories stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $225,182.00. Following the completion of the sale, the senior vice president directly owned 6,377 shares of the company’s stock, valued at approximately $570,741.50. The trade was a 28.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO John Sakys sold 2,827 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $89.50, for a total value of $253,016.50. Following the transaction, the chief financial officer directly owned 19,785 shares of the company’s stock, valued at approximately $1,770,757.50. This represents a 12.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 8,277 shares of company stock worth $770,122. Company insiders own 2.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. boosted its holdings in Mesa Laboratories by 5,366.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 322 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Mesa Laboratories in the 4th quarter valued at about $27,000. Kestra Advisory Services LLC purchased a new position in shares of Mesa Laboratories in the 4th quarter valued at about $55,000. BNP Paribas Financial Markets lifted its stake in shares of Mesa Laboratories by 30.9% in the third quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock valued at $69,000 after purchasing an additional 243 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in Mesa Laboratories by 432.9% during the second quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock worth $79,000 after buying an additional 684 shares in the last quarter. 90.60% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, June 3rd. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Mesa Laboratories presently has an average rating of “Reduce” and a consensus target price of $94.00.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.